Samsung Biologics makes $1.8 billion all-cash offer for Switzerland's PolyPeptide Group
South Korea's Samsung Biologics announced an all-cash bid of 1.46 billion Swiss francs ($1.8 billion) for Switzerland's PolyPeptide Group. The deal is seen as a move to expand Samsung's pharmaceutical manufacturing supply chain.